Chemoprotectants: A review of their clinical pharmacology and therapeutic efficacy

Drugs

Volumn 57, Issue 3, 1999, Pages 293-308

  Links, Matthew ^a   Lewis, Craig ^a  

^a PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; 2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; ALKYLATING AGENT; AMIFOSTINE; ANTHRACYCLINE; BIS[2 (3 AMINOPROPYLAMINO)ETHYL] DISULFIDE; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; FLUOROURACIL; FOLINIC ACID; FREE RADICAL; GLUTATHIONE; HEMOPOIETIC GROWTH FACTOR; IRON; MESNA; OXAZAPHOSPHORINE; RAZOXANE;

ANTINEOPLASTIC ACTIVITY; BONE MARROW TOXICITY; CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DRUG BINDING; DRUG TOXICITY; HEMORRHAGIC CYSTITIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; OTOTOXICITY; QUALITY OF LIFE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

ADRENOCORTICOTROPIC HORMONE; AMIFOSTINE; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; FEMALE; GLUTATHIONE; HUMANS; MESNA; PEPTIDE FRAGMENTS; PROTECTIVE AGENTS; RADIATION-PROTECTIVE AGENTS; RAZOXANE;

EID: 0033014520     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957030-00003     Document Type: Review

References (94)

1. Telcher BA. Antitumour alkylating ageents. In: De Vita VT, Hellman S, Rosenberg S, editors. Cancer: principles and practices or oncology. Philadelphia (PA): Lippincott-Raven, 1997: 405-18
2. Nagai N, Hotta K, Yamamura H, et al. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in the rat kidney: protective effects against cisplatin nephrotoxicity. Cancer Chemother Pharmacol 1995; 36 (5): 404-10
3. Capizzi RI. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (ethyol). Eur J Cancer 1996; 32A (Suppl. 4): S5-16
4. Yang JL, Fernandes DJ, Speicher L, et al. Biochemical determinants of the cytoprotective effect of amifostine [abstract]. Proc Am Assoc Cancer Res 1995; 36: 290
5. List A, Brasfield F, Heaton R, et al. Stimulation of haematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 1997; 90: 3364-9
6. Nagy B, Grdina DJ. Protective effects of 2-|(aminopropyl)-aminol ethanethiol against bleomycin and nitrogen mustard-induced mutagenicity in V79 cells. Int J Radiat Oncol Biol Phys 1986; 12: 1475-8
7. Glick JH, Glover DJ, Weiler C, et al. Phase I controlled trials of WR-2721 and cyclophosphamide. Int J Radiat Oncol Biol Phys 1984; 10: 1777-80
8. Glover D, Glick JH, Weiler C, et al. Phase I trials of WR-2721 and cisplatin. Int J Radiat Oncol Biol Phys 1984; 10: 1781-4
9. Van der Vijgh WJF, Korst AEC. Amifostine (ethyol): pharmacokinetic and pharmacodynamic effects in vivo. Eur J Cancer 1996; 32A (Suppl. 4): s26-30
10. Adamson PC, Balis FM, Belasco JE, et al. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res 1995; 55: 4069-72
11. Schiller JH, Storer B, Berlin J, et al. Amifostine, cisplatin and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol 1996; 14: 1913-21
12. Glover D, Glick JH, Weiler C, et al. WR-2721 and high dose cisplatin: an active combination in the treatment of metastatic melanoma. J Clin Oncol 1987; 5 (4): 574-8
13. Kemp G, Rose P, Lurain J, et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996; 14: 2101-12
14. Bukowski RM. Amifostine (ethyol): dosing, administration and patient management guidelines. Eur J Cancer 1996; 32A (Suppl. 4): S46-9
15. Wadler S, Haynes H, Beitler JJ, et al. Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. J Clin Oncol 1993; 11 (8): 1517-22
16. Glover D, Glick JH, Weiler C, et al. WR-2721 protects against the haematological toxicity of cyclophosphamide: a controlled phase II trial. J Clin Oncol 1986; 4: 584-8
17. Shpall E, Stemmer S, Hami L, et al. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide - purged bone marrow in breast cancer patients receiving high dose chemotherapy with autologous bone marrow support. Blood 1994; 83: 3132-7
18. Poplin EA, Lorusso P, Lokich JJ, et al. Randomised clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 1994; 33: 415-9
19. Betticher DC, Anderson H, Ranson M, et al. Carboplaltin combined with amifostine, a bone marrow protectant in the treatment of non-small cell lung cancer: a randomised phase II study. Br J Cancer 1995; 72: 1551-5
20. Budd GT, Ganapathi R, Adelstein DJ, et al. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumours. Cancer 1997; 80: 1134-40
21. Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health Syst Pharm 1995; 52 (10): 2208-12
22. Pernkopf I, Tesch G, Dempe K, et al. Binding of epirubicin to human plasma proteins and red blood cells - in vitro interaction with the cytoprotectant amifostine. Pharmazie 1996; 51 (11): 897-901
23. Elakawi Z. Zdanowics J, Creaven PJ, et al. Induction gamma glutamyl transpeptidase mRNA by platinum complexes in a human ovarian carcinoma cell line. Oncol Res 1996; 8 (10-11: 415-23
24. Zunino F, Pratesi G, Micheloni A, et al. Protective effect of reduced glutathione against cisplatin induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumour drug. Chem Biol Interact 1989; 70: 89-101
25. Tedeschi M, De Cesare A, Oriana S, et al. The role of glutathione in combination with cisplatin in the treatment of ovarian cancer. Cancer Treat Rev 1991; 18: 253-9
26. Perego P, Paolicchi A, Tongiani R, et al. The cell specific antiproliferative effect of reduced glutathione is mediated by gamma-glutamyl transpeptidase-dependent extracellular pro-oxidant reactions. Int J Cancer 1997; 71: 246-50
27. Hamers FPT, Braklee JH, Cavaletti E, et al. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res 1993; 53: 544-9
28. Cavaletti G, Minoia C, Schieppati M, et al. Protective effects of glutathione on cisplatin neurotoxicity in rats. Int J Radiat Oncol Biol Phys 1994; 29 (4): 771-6
29. Leone R, Fracasso ME, Soresi E, et al. Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin. Cancer Chemother Pharmacol 1992; 29: 385-90
30. Di Re F, Bohm S, Oriana S, et al. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. Ann Oncol 1993; 4: 55-61
31. Fontanelli R, Spatti G, Raspagliesi F, et al. A preoperative single course of high dose cisplatin and bleomycin with glutathione protection in bulky stage IB/II carcinoma of the cervix. Ann Oncol 1992; 3: 117-21
32. Parnis FX, Coleman RE, Harper PG, et al. A randomised double blind placebo controlled clinical trial assessing the tolerability and efficacy of glutathione as an adjuvant to escalating doses of cisplatin in the treatment of advanced ovarian cancer. Eur J Cancer 1995; 31A: 1721
33. Bogliun G, Marzorati L, Marzola M, et al. Neurotoxicity of cisplatin +/- reduced glutathione in the first line treatment of advanced ovarian cancer. Int J Gynaecol Cancer 1996; 6: 415-9
34. Colombo N, Bini S, Micelli D, et al. Weekly cisplatin +/- glutathione in relapsed ovarian carcinoma. Int J Gynaecol Cancer 1995; 5: 81-6
35. Cascinu S, Cordella L, Del Ferro E, et al. Neuroprotective effect of reduced glutathione on cisplatin-bound chemotherapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 1995; 13 (1): 26-32
36. De Konig P, Brakkee JH, Gispen WH. Methods for producing a reproducible crush injury in the sciatic and tibial nerve of the rat and rapid and precise testing of return of sensory function: beneficial effects of melanocortins. J Neurol Sci 1986; 74: 237-46
37. Van der Hoop RG, Hamers FPT, Neijt JP, et al. Protection against cisplatin induced neurotoxicity by ORG 2766: histological and electrophysiological evidence. J Neurol Sci 1994; 126: 109-15
38. Hamers FPT, Pette C, Neijt JP, et al. The ACTH(4-9) analog, ORG 2766, prevents taxol-induced neuropathy in rats. Eur J Pharmacol 1993; 233: 177-8
39. Gerritsen van der Hoop R, Vecht CJ, van der Burg MEL, et al. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med 1990; 322: 89-94
40. van Gerven JMA, Hovestadt A, Moll JWB, et al. The effects of ACTH (4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trial. J Neurol 1994; 241: 432-5
41. Hovestadt A, van ber Burg ME, Verbiesl HB, et al. The course of neuropathy after cessation of cisplatin treatment combined with ORG-2766 or placebo. J Neurol 1992; 239: 143-6
42. Roberts JA, Jenison EL, Kim K, et al. A randomized multicenter, double-blind, placebo-controlled, dose-finding study of ORG-2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol Oncol 1997; 67: 172-7
43. Young RC, Ozols RF, Myers CE. The anthracycline antineoplastic drugs. N Engl J Med 1981; 305: 139-53
44. Pigram WJ, Fuller W, Amilton LDH. Stereochemistry of intercalations: interaction of daunomycin with DNA. Nature 1972; 235: 17-9
45. Twewy KM, Rowe TC, Yang L, et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466-8
46. Lenaz L, Page JA. Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev 1976; 3: 111-20
47. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-7
48. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-15
49. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672-7
50. Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria: anthracycline radical formation by NADPH dehydrogenase. J Biol Chem 1986; 261: 3060-7
51. Bachur NR, Gordon SL, Gee MV. A general mechanism for microsomal activation of quinone anticancer agents to free radicals. Cancer Res 1978; 38: 1745-50
52. Goodman J, Hochstein P. Generation of free radicals and lipid peroxidation by redox cycling of Adriamycin and daunomycin. Biochem Biophys Res Commun 1977; 7: 797-803
53. Doroshow JH, Locker GY, Baldinger J, et al. The effect of doxorubicin on hepatic and cardiac glutathione. Res Commun Chem Pathol Pharmacol 1979; 36: 285-95
54. Myers CE, Bonow R, Palmeri S, et al. A randomised controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol 1983; 10 Suppl. 1: 53-5
55. Legha S, Wang YM, Mackay B, et al. Clinical and pharmacological investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity. Ann N Y Acad Sci 1982; 393: 411-8
56. 2 reduction by the iron complexes of adriamycin and daunomycin; the importance of the sidechain hydroxyl group. Biochem Biophys Acta 1986; 884: 326-36
57. Sugioka KA, Nakano M. Mechanisms or phospholipid peroxidation induced by ferric iron-ADP adriamycin co-ordination complex. Biochem Biophys Acta 1982; 713: 333-43
58. Herman FH, Mhatre R, Chadwick D. Modification of some of the toxic effects of daunomycin (NSC-82151) by pre-treatment with anti-neoplastic agents ICRF-159 (NSC-129943). Toxicol Appl Pharmacol 1974; 27: 517-26
59. Herman EH, Witiak DT, Hellman K, et al. Biological properties of ICRF-159 and related bisdioxopiperazine compounds. Adv Pharmacol Chemother 1985; 19: 249-301
60. Wang G, Finch MD, Trevan D, et al. Reduction of daunomycin toxicity by razoxane. Br J Cancer 1981; 43: 871-7
61. Yeung TK, Jaenke RS, Wilding D, et al. The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat. Cancer Chemother Pharmacol 1992; 30: 58-64
62. Herman EH, Ferrans VJ. Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits. Cancer Chemother Pharmacol 1986; 16: 102-6
63. Liesman J, Belt R, Haas C, et al. Phase I evaluation of ICRF-187 in the treatment of patients with advanced malignancy. Cancer 1981; 47: 1959-62
64. Von Hoff DD, Howser D, Lewis BJ, et al. Phase I study of ICRF-187 using a daily for 3 days schedule. Cancer Treat Rep 1981; 65: 249-52
65. Speyer JL, Green MD, Kramer E, et al. Protective effects of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N Engl J Med 1988; 319: 745-52
66. Speyer JL, Green MD, Zeleniuch-Jucquotte A, et al. TCRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol 1992; 10: 117-27
67. ten Bokkel-Huinink WW. Schreuder JE, Dubbleman R, et al. ICRF-187 protects against doxorubicin induced cardiomyopathy [abstract]. Ann Oncol 1992; 3 Suppl 1: A221
68. Weisberg SR, Rosenfeld CS, York RM, et al. Dexrazoxane (ADR 529. ICRF-187, Zinecard) protects against doxorubicin-induced chronic cardiotoxicity. Proc Am Soc Clin Oncol 1992; 11: 190
69. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol 1997; 15: 1318-32
70. Venturini M, Michelotti A, Del Mastro L, et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol 1996; 14: 3112-20
71. Feldman JE, Jones SE, Weisberg SR, et al. Advanced small cell lung cancer treated with CAV chemotherapy and cardioprotective agent dexrazoxane (ADR-529, ICRF-187, Zinecard). Proc Am Soc Clin Oncol 1992; 11: 993
72. Wexler LH. Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996; 14: 362-72
73. Swain SM, Whaley FS, Gerber MC, et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol 1997; 15: 1333-40
74. Hochster H, Liabes L, Wadler S, et al. Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed dose doxorubicin. J Natl Cancer Inst 1992; 84: 1725-30
75. Basser RL, Sobol MM, Duggan G, et al. Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy. J Clin Oncol 1994; 12: 1659-66
76. Bryant BM, Jarman M, Ford HT. Prevention of ifosphosphamide-induced urothelial toxicity with 2-mercaptocthane sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet 1980; II: 657-9
77. Cox PJ. Cyclophosphamide cystitis: identification of acrolein as the causative agent. Biochem Pharmacol 1979; 28: 2045-9
78. Fleming RA, Cruz JM, Webb CD, et al. Urinary elimination of cyclophosphamide alkylating metabolites and free thiols following two administration schedules of high-dose cyclophosphamide and mesna. Bone Marrow Transplant 1996; 17: 497-501
79. Brock N, Pohl J, Stekar J, et al. Studies on the urotoxicity of oxazaphosphorine cystostatics and its prevention - III: profile of action of sodium 2-mercaptoethane sulfonate (Mesna). Eur J Cancer Clin Oncol 1982; 18: 1377-87
80. Scheef W, Klein HO, Brock N, et al. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results. Cancer Treat Rep 1979; 63: 501-5
81. Fukuoka M, Negoro S, Masuda N, et al. Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. J Cancer Res Clin Oncol 1991; 117: 473-8
82. Vose JM, Reed EC, Pippert GC, et al. Mesna compared with continuous bladder irrigation as uroprotection during high dose chemotherapy and transplantation: a randomized trial. J Clin Oncol 1993; 11: 1306-10
83. Munshi NC, Lochrer Sr PJ, Williams SD, et al. Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumours. Invest New Drugs 1992; 10: 159-63
84. Legha S, Papadopoulos N, Plager C, et al. A comparative evaluation of the uroprotective effect mercaptoethane sulfonate (mesna) and N-acetylcysteine (NAC) in sarcoma patients treated with ifosfamide. Proc Am Soc Clin Oncol 1990; 9: 1205
85. Pohl VJ, Brock N, Schneider B, et al. Zur Pharmakokinetik von uromitexan. Methods Find Exp Clin Pharmacol 1981; 3 Suppl. 1: 95-101
86. Burkert H. Clinical overview of mesna. Cancer Treat Rev 1983; 10: 175-81
87. Burkert H, Lucker PW, Wetzelsberger N, et al. Bioavailability of orally administered mesna. Arzneimittel Forschung 1984; 34: 1597-600
88. Katz A, Epelman S, Anelli A, et al. A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficacy and simplified administration. J Cancer Res Clin Oncol 1995; 121: 128-31
89. Dorr RT. Chemoprotectants for cancer chemotherapy. Semin Oncol 1991; 18 Suppl. 2: 48-58
90. Goren MP. Oral administration of mesna with ifosfamide. Semin Oncol 1996; 23 Suppl. 6: 91-6
91. Cerny T, Graf A, Rohner P, et al. Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility. J Cancer Res Clin Oncol 1991; 117 Suppl. 4: 129-34
92. Markman M, Kennedy A, Webster K, et al. Continuous subcutaneous administration of mesna to prevent ifosfamide-induced haemorrhagic cystitis. Semin Oncol 1996; 23 Suppl. 6: 97-8
93. Benyoussef IC, Bottlaender A, Pfister HR, et al. Allergic contact dermatitis from mesna. Contact Dermatitis 1996; 34: 228-9
94. Reinhold-Keller E, Mohr J, Christophers E, et al. Mesna side-effects which imitate vasculitis. Clin Invest 1992; 70: 698-704